CanSinoBIO’s Convidecia™ Approved as Heterologous Booster in China
- Saturday, February 19, 2022, 7:10
- Business
- Add a comment
TIANJIN, China, Feb. 19, 2022 /PRNewswire/ — CanSino Biologics Inc. (“CanSinoBIO”) (SSE: 688185, HKEX: 06185) today announced that its Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (“Ad5-nCoV”, trade name: Convidecia™) has been approved by the Joint Prevention and…
About the Author
adminasapcorp has written 41790 stories on this site.